135 related articles for article (PubMed ID: 11410415)
21. A second mutation in the methylenetetrahydrofolate reductase gene and the risk of venous thrombotic disease.
Franco RF; Morelli V; Lourenço D; Maffei FH; Tavella MH; Piccinato CE; Thomazini IA; Zago MA
Br J Haematol; 1999 May; 105(2):556-9. PubMed ID: 10233437
[TBL] [Abstract][Full Text] [Related]
22. Association between genotype and plasma levels of thrombin-activated fibrinolysis inhibitor (TAFI) in the development of preeclampsia.
Acosta-Tejeda M; Baptista-González H; Rosenfeld-Mann F; Trueba-Gómez R; García-Latorre E
Thromb Res; 2011 Oct; 128(4):e39-42. PubMed ID: 21708401
[TBL] [Abstract][Full Text] [Related]
23. Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis.
Martinez-Zamora MA; Tassies D; Carmona F; Espinosa G; Cervera R; Reverter JC; Balasch J
Am J Reprod Immunol; 2009 Dec; 62(6):381-9. PubMed ID: 19895374
[TBL] [Abstract][Full Text] [Related]
24. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
Ricart JM; Ramón LA; Vayá A; España F; Santaolaria ML; Todolí J; Castelló R; Fontcuberta J; Estellés A
Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
[TBL] [Abstract][Full Text] [Related]
25. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.
Santamaría A; Borrell M; Oliver A; Ortín R; Forner R; Coll I; Mateo J; Souto JC; Fontcuberta J
Am J Hematol; 2004 Aug; 76(4):348-52. PubMed ID: 15282667
[TBL] [Abstract][Full Text] [Related]
26. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
Chengwei X; Xiaoli M; Yuan Z; Li P; Shengjiang W; Chao Y; Yunshan W
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):698-703. PubMed ID: 23624357
[TBL] [Abstract][Full Text] [Related]
27. Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.
Heylen E; Miljic P; Willemse J; Djordjevic V; Radojkovic D; Colovic M; Elezovic I; Hendriks D
Thromb Res; 2009 Sep; 124(4):427-32. PubMed ID: 19195685
[TBL] [Abstract][Full Text] [Related]
28. Association between estrogen receptor alpha and beta gene polymorphisms and deep vein thrombosis.
Aléssio AM; Höehr NF; Siqueira LH; Ozelo MC; de Pádua Mansur A; Annichino-Bizzacchi JM
Thromb Res; 2007; 120(5):639-45. PubMed ID: 17184825
[TBL] [Abstract][Full Text] [Related]
29. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
[TBL] [Abstract][Full Text] [Related]
30. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
Paola Cellai A; Antonucci E; Alessandrello Liotta A; Fedi S; Marcucci R; Falciani M; Giglioli C; Abbate R; Prisco D
Thromb Res; 2006; 118(4):495-500. PubMed ID: 16318869
[TBL] [Abstract][Full Text] [Related]
31. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation.
Ladenvall C; Gils A; Jood K; Blomstrand C; Declerck PJ; Jern C
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):955-62. PubMed ID: 17272741
[TBL] [Abstract][Full Text] [Related]
32. Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study.
Kozian DH; Lorenz M; März W; Cousin E; Mace S; Deleuze JF
Thromb Haemost; 2010 May; 103(5):976-83. PubMed ID: 20216989
[TBL] [Abstract][Full Text] [Related]
33. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
[TBL] [Abstract][Full Text] [Related]
34. Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.
Tàssies D; Roqué M; Monteagudo J; Martorell T; Sionis A; Arzamendi D; Heras M; Reverter JC
Thromb Res; 2009 Nov; 124(5):614-8. PubMed ID: 19699511
[TBL] [Abstract][Full Text] [Related]
35. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.
Guven GS; Kiliçaslan A; Oz SG; Haznedaroglu IC; Kirazli S; Aslan D; Sözen T
Clin Appl Thromb Hemost; 2006 Jul; 12(3):364-8. PubMed ID: 16959692
[TBL] [Abstract][Full Text] [Related]
36. Thrombin activatable fibrinolysis inhibitor (TAFI): relationship to hemostatic alteration in patients with beta-thalassemia.
Mokhtar GM; Matter RM; Shawki H; Abdel Aziz MM
Pediatr Hematol Oncol; 2010 Aug; 27(5):363-73. PubMed ID: 20670166
[TBL] [Abstract][Full Text] [Related]
37. TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction.
Akatsu H; Yamagata H; Chen Y; Miki T; Kamino K; Takeda M; Campbell W; Kondo I; Kosaka K; Yamamoto T; Okada H
Br J Haematol; 2004 Nov; 127(4):440-7. PubMed ID: 15521922
[TBL] [Abstract][Full Text] [Related]
38. Assessment of the role of thrombin activatable fibrinolysis inhibitor in retinal vein occlusion.
Gumus K; Kadayifcilar S; Eldem B; Ozcebe O
Retina; 2007 Jun; 27(5):578-83. PubMed ID: 17558319
[TBL] [Abstract][Full Text] [Related]
39. The impact of single nucleotide polymorphisms of the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI antigen levels in healthy children and pediatric oncology patients.
Knoefler R; Ludwig K; Kostka H; Kuhlisch E; Siegert G; Suttorp M
Semin Thromb Hemost; 2003 Dec; 29(6):575-83. PubMed ID: 14719174
[TBL] [Abstract][Full Text] [Related]
40. The fibrinogen gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis.
Grünbacher G; Weger W; Marx-Neuhold E; Pilger E; Köppel H; Wascher T; März W; Renner W
Thromb Res; 2007; 121(1):33-6. PubMed ID: 17445871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
